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Abstract Historically, bipolar disorder has been conceptu-
alized as a disease involving episodic rather than chronic
dysfunction. However, increasing evidence indicates that
bipolar disorder is associated with substantial inter-episode
psychosocial and vocational impairment. Here we review
the contributions of neurocognitive deficits and structural
and functional neuroanatomic alterations to the observed
functional impairments. In particular, compelling evidence
now suggests that neurocognitive impairments, particularly
in the areas of attention, processing speed, and memory, are
associated with functional outcome. Although investigation
of the neural correlates of functional disability in bipolar
disorder is only in its nascent stages, preliminary evidence
suggests that white matter abnormalities may be predictive
of poor outcome. A better understanding of the relationship
between neurocognitive and neuroimaging assays and
functional outcome has the potential to improve current
treatment options and provide targets for new treatment





There is growing recognition that bipolar affective disorder
is associated with neurocognitive deficits and allied
neuroanatomic and neurophysiologic anomalies [1, 2￿].
While mood states and psychotropic medication usage
influence cognition and brain physiology, observations that
many of these neurocognitive and structural and functional
neuroanatomic abnormalities predate symptom onset or
persist during symptom remission raise the possibility that
some changes in brain structure and function are central to
the pathophysiology of bipolar affective disorder [3, 4].
Furthermore, accumulating evidence suggests that neuro-
cognitive and neuroimaging factors are associated with
clinical outcome, psychosocial functioning, and vocational
disability in bipolar disorder [5]. The goal of this review is
to synthesize these recent findings to assess their clinical
relevance and highlight areas in need of additional research.
Almost two thirds of bipolar patients have some level of
inter-episode functional impairment [6, 7], and about half
are unemployed or have reduced occupational functioning
[8]. Thus, although many individuals with bipolar disorder
respond well to treatments designed to reduce affective and
psychotic symptoms, the ability to achieve functional
recovery—the capacity to study, work, engage in recreation,
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may be significantly hindered. Therefore, recovery from
mood episodes and/or residual symptoms does not necessar-
ily translate into functional recovery. Indeed, many patients
with bipolar illness do not regain premorbid levels of
psychosocial functioning [9]. Studies of the lifetime course
of bipolar disorder consistently find that during periods of
symptomatic recovery, bipolar individuals often continue to
experience residual mood symptoms that likely contribute to
increased levels of disability and decreased psychosocial
functioning [10]. Clinical factors—in particular disease
chronicity, severity, and subsyndromal depressive symp-
toms—are associated with poor functional outcome [5, 11].
In addition, as reviewed in detail below, there is growing
evidence for a relationship between neurocognitive function,
underlying neuroanatomic abnormalities, and functional
outcome across a range of severe neuropsychiatric disorders,
including bipolar illness [12–14]. A better understanding of
the relationship between neurocognitive and neuroimaging
measures and clinical outcome has the potential to improve
current treatment options and provide targets for new
treatment strategies.
Neurocognitive Findings in Bipolar Disorder
Although there is clear evidence that patients with bipolar
disorder exhibit widespread neurocognitive dysfunction
during acute episodes of mania and depression, the discovery
that these deficits endure during symptom remission raises
the possibility that cognitive impairment may represent a trait
rather than a state variable [3]. Euthymic bipolar patients
exhibit limitations in several cognitive domains, particularly
in measures of executive function, declarative memory, and
sustained attention [1, 15–17]. Although euthymic patients
often present with residual affective symptoms that may
adversely affect performance on cognitive tests [18], even
those who have been euthymic for months prior to
assessment have marked neuropsychological impairments
[19]. Indeed, several recent meta-analyses of neuropsycho-
logical performance in euthymic bipolar disorder have
documented impairment across a wide variety of cognitive
domains [1, 15–17]. In the most recent of these meta-
analyses, Kurtz and Gerraty [1] found that nonsymptomatic
bipolar patients performed 0.4–0.9 SD below healthy
individuals on measures of attention (e.g, Continuous
Performance Test; Cohen’s d=0.69), processing speed (e.g,
digit symbol substitution; d=0.66), working memory (e.g,
Digit Span Backward; d=0.65), declarative memory (e.g,
Rey or California Verbal Learning Test; d=0.81), nonverbal
declarative memory (e.g, visual reproduction subtest from the
Wechsler Memory Scale; d=0.91), and executive functioning
(e.g, Trail Making Test B; d=0.72). Observations of
neuropsychological deficits in nonsymptomatic bipolar
patients suggest that these impairments may be related to
the pathophysiology of the illness and, as described
subsequently, are also reasonable predictors of psychosocial
functioning and disability [20￿].
Evidence that clinically unaffected relatives of patients
with bipolar disorder have subtle neurocognitive impair-
ments suggests that such deficits may reflect genetic
liability for the illness. A recent meta-analysis reported
small but statistically significant differences (e.g, d<0.5)
for unaffected first-degree relatives compared with healthy
individuals in the domains of executive functioning and
verbal memory [17]. Another recent meta-analysis of 17
published studies included 443 first-degree relatives of
bipolar patients and reported cognitive impairments in the
range of small to medium effect sizes in the domains of
attention (0.08–0.51), verbal learning (0.27–0.33), and exec-
utive functioning (0.22–0.36) [21]. Glahn and colleagues
[22￿] recently reported that three cognitive tests (Digit
Symbol Coding, Object Delayed Response Task, and
Immediate Facial Memory) are genetically correlated with
liability for bipolar disorder, suggesting that the same genetic
factors that increase the risk of bipolar disorder influence
performance on these tests.
Although many of the neurocognitive impairments found
in individuals with bipolar disorder are present during
euthymia, it is quite likely that clinical course influences
test performance in bipolar disorder. Indeed, age at onset,
total number of mood episodes, number of manic episodes,
number of depressive episodes, and number and duration of
hospitalizations are all factors associated with the degree of
neurocognitive impairment among individuals with bipolar
disorder [15]. Furthermore, the use of psychotropic medi-
cation could impact neurocognitive functioning in bipolar
patients. A recent meta-analysis examining the effects of
lithium on cognitive performance in bipolar disorder in 12
studies involving 276 lithium-treated and 263 lithium-free
patients found a small but significant impairment in
lithium-treated patients in immediate verbal learning and
memory (effect size, 0.24) and creativity (effect size, 0.33)
[5]. In contrast, no significant impairments were found for
delayed verbal memory, visual memory, attention, executive
functioning, processing speed, or psychomotor performance.
Some antidepressant medications have been shown to yield
adverse cognitive effects, particularly those with anticholin-
ergic properties [23]. However, other studies have failed to
find significant effects of such medications on cognition [24,
25]. Although few studies have examined neurocognitive
performance in unmedicated bipolar patients, Goswami and
colleagues [26] found no significant differences in neuro-
cognitive test performance between 22 drug-free euthymic
bipolar patients and 22 medicated euthymic patients.
Together, these data suggest that although clinical course
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in bipolar disorder, these effects seem to explain only a
fraction of the observed impairments.
Growingevidenceindicatesthattheneurocognitiveimpair-
ments contribute to poorer psychosocial functioning and
increased functional disability in bipolar disorder [12–14,
20￿, 27, 28]. For example, executive dysfunction at initial
assessment has been linked to lower levels of functional
recovery in this population both cross-sectionally and longi-
tudinally [13, 14, 28]. Bonnin and colleagues [29￿]r e c e n t l y
found that subthreshold depressive symptoms and working
memory function (digits backward) were specific predictors
of occupational functioning 4 years later. Similarly, bipolar
patients with declarative memory deficits are less likely to
return to premorbid psychosocial or occupational functioning
[11, 14, 28, 29￿].
Schizophrenia research has recently begun to distinguish
between functional capacity (i.e, an estimate of one’s ability
to perform tasks relevant to everyday functioning) and
actual performance (i.e, what one actually does in everyday
settings). This distinction is important, as performance can
be influenced by functional capacity as well as environ-
mental, motivational, and other factors. Bowie and col-
leagues [20￿] recently performed a series of confirmatory
path analyses to determine how neurocognitive deficit
influences real world functioning and disability in bipolar
disorder. A total of 130 community-dwelling individuals
with bipolar disorder were assessed with neuropsycholog-
ical tests, symptom measures, and performance-based social
and adaptive functional competence measures in three
domains of real world functioning (community and house-
hold activities, work skills, and interpersonal relationships).
In all models, the relationship between neurocognition and
outcome was largely mediated by competence. Neuro-
cognition was related to activities directly and through a
mediated relationship with adaptive competence. In con-
trast, work skills were entirely mediated by adaptive and
social competence. The relationship between neurocogni-
tion and interpersonal relationships was mediated by social
competence. These findings imply that functional disability
may persist in patients with bipolar disorder even after
symptomatic recovery due to neurocognitive and skill
deficits. Conversely, even if a patient acquires certain
neurocognitive skills but continues to experience mild
mood symptomatology, changes in real world behavior
might lag or not manifest at all.
In summary, significant evidence suggests that many
individuals with bipolar disorder have at least some degree
of neurocognitive deficit. Although these deficits may be
influenced by clinical course/severity or psychotropic medi-
cation usage, they also seem to be associated with the genetic
liability for the illness, suggesting that neurocognitive deficits
are an important aspect of the presentation of bipolar disorder.
Finally, neurocognitive impairments impact real world func-
tioning of patients with bipolar disorder.
Neuroanatomic Findings in Bipolar Disorder
The most consistently documented neuroanatomic abnor-
malities in adult patients with bipolar disorder are lateral
ventricle enlargement (+17%) and increased rates of deep
white matter hyperintensities (Odds Ratio, 2.49) [2￿].
Reduced area or volume of the corpus callosum is also a
robust finding across studies [30]. Additional evidence for
white matter involvement in bipolar disorder comes from
studies finding alterations in white matter tract organization
[31, 32] and regional white matter volume reductions [33].
In addition, some recent evidence indicates that white matter
abnormalities may be stable, trait-based abnormalities that
reflect genetic liability to the illness [31, 34]. Kieseppa and
colleagues [33] found decreased left hemisphere white matter
volume in bipolar probands and their nonbipolar co-twins.
Similarly, McDonald and colleagues [34] found that the
genetic risk of bipolar disorder was associated with white
matter reduction in the left frontal and temporoparietal
regions, suggesting that left frontotemporal disconnectivity
may be a genetically controlled neuroanatomic abnormality
associated with bipolar illness. Finally, in a large Dutch twin
sample, van der Schot and colleagues [35￿] found that
reduction in overall white matter volume was related to the
genetic risk of bipolar disorder, whereas significant environ-
mental correlations were observed for cortical gray matter.
In general, findings of gray matter alterations in bipolar
disorder are more variable across studies, which is likely at
least partially attributable to the now well-documented
effects of lithium on gray matter volume [2￿, 36]. Although
a recent meta-analysis revealed an effect size of 1.17 for
reduced volume of the left anterior cingulate in bipolar
patients relative to controls, this finding was not significant
across studies due to the high between-study heterogeneity
[2￿]. Kempton and colleagues [37], using voxel-based
morphometry inpatientswithbipolar I disorder, their relatives
with major depression, healthy relatives, and controls, found
group differences in the left insula, cerebellum, and substantia
nigra;increasedleftinsulavolumeinparticularwasassociated
with genetic preposition to bipolar disorder independent of
clinical phenotype. In contrast, increased left substantia nigra
volume was specific to those with the clinical phenotype of
bipolar I disorder. Changes uniquely associated with the
absence of a clinical diagnosis in bipolar relatives were
observed in the left cerebellum, suggesting that there may be
dissociable genetic and phenotypic influences on brain
structure in bipolar disorder.
Given the substantial body of literature on neuroana-
tomic changes in bipolar disorder [2￿], surprisingly few
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patients with schizophrenia and those at risk of the illness,
this relationship has been examined in several studies. For
example, accelerated ventricular enlargement in the 3 years
following illness onset was associated with poor outcome in
first-episode schizophrenia, whereas a progressive decre-
ment in frontal lobe white matter was associated with
greater negative symptom severity [38]. More recently
Karlsgodt and colleagues [39] found that the structural
integrity of medial temporal white matter tracts was
predictive of functional outcome in adolescents at high risk
of developing psychosis. Given the accumulating evidence
that disrupted white matter integrity may be central to the
pathophysiology of bipolar disorder, white matter abnor-
malities represent a promising candidate for a neuroana-
tomic predictor of outcome.
Two prior studies examined white matter hyperinten-
sities as indicators of treatment resistance [40] and poor
outcome [41] in bipolar disorder. Moore and colleagues
[41] categorized patients with bipolar disorder as good or
poor outcome based on treatment response and level of
functioning, finding that poor outcome group members had
significantly more deep and more severe subcortical
punctate white matter hyperintensities relative to those in
the good outcome group and healthy controls. Regenold
and colleagues [40] found that an index of treatment
resistance correlated significantly with deep white matter
hyperintensity volume, as well as measures of abnormal
brain glucose metabolism (sorbitol and fructose) in bipolar
patients but not in other patients (i.e, those with schizophrenia
and neurologic controls).
In summary, there is strong evidence to date implicating
neurocognitive factors in bipolar patients as key determinants
of functional outcome. Given that these cognitive abnormal-
ities likely are reflective of underlying abnormalities in brain
structure and function, we propose that microstructural white
matter alterations may contribute to poor outcome.
Functional Neuroimaging Findings in Bipolar Disorder
Similar to the literature relating abnormalities of brain
structure to poor outcome in schizophrenia, recent func-
tional MRI studies also have begun to document such a
relationship. In particular, Fusar-Poli and colleagues [42]
found that in youth with prodromal signs of psychosis,
clinical and functional improvement over follow-up was
associated with a longitudinal increase in activation in the
anterior cingulate and right parahippocampal gyrus during
performance on an N-back task. Similarly, in individuals at
high clinical risk of psychosis, Sabb and colleagues [43]
found that baseline neural activity in the left inferior frontal
gyrus during performance on a language processing task
was predictive of severity of positive formal thought
disorder and poor social outcome at follow-up.
To date, no such studies have been conducted in patients
with bipolar disorder. However, emerging literature sug-
gests that the neurophysiology of bipolar disorder involves
frontal hypoactivation with concomitant disinhibition (i.e,
relative hyperactivation) of limbic structures [44, 45]. The
subgenual prefrontal cortex modulates the affective output
of limbic and paralimbic structures and cognitive output
from the prefrontal cortex. Recent evidence from functional
MRI studies using affective processing paradigms (ie,
reacting to stimuli with positive or negative emotional
valence) suggests that patients with bipolar disorder may
disproportionately engage limbic structures during emo-
tionally valent tasks, regardless of mood state [46, 47],
although the direction of effects has not been consistent
across studies. Taken together, these studies suggest that
corticolimbic dysregulation may underlie the emotional
dysregulation and cognitive impairments associated with
bipolar disorder [45, 48]. Moreover, exaggerated medial
prefrontal cortical and subcortical (putamen and amygdala)
responses to emotional signals have been observed in
bipolar I patients and their nonbipolar relatives, suggesting
that such responses may represent heritable neurobiological
abnormalities underlying bipolar disorder [49].
Implications for Treatment
Given that similar cognitive impairments and associated
psychosocial and functional disabilities are seen in patients
with bipolar disorder and those with schizophrenia, the
adaptation of treatment strategies that have proven beneficial
for schizophrenia patients may also be efficacious for bipolar
patients. In particular, cognitive remediation has been associ-
ated with significant, although modest, improvements in
cognitive performance and psychosocial functioning in
schizophrenia patients [50]. However, treatment of cognitive
impairment in bipolar illness remains largely unexplored.
The development of treatments that target cognitive impair-
ments and functional status is an important area of future
investigation in bipolar disorder. Two small studies have
found that rehabilitative interventions such as cognitive
remediation and supported employment may be effective in
improving vocational outcomes for bipolar patients, but this
will require replication in larger investigations [9].
Conclusions
Although bipolar disorder historically has been viewed as a
disease involving only episodic dysfunction, increasing
evidence indicates that this is not the case for a substantial
502 Curr Psychiatry Rep (2010) 12:499–504proportion of patients. Collectively, the data reviewed
above provide compelling evidence that cognitive impair-
ments are present across multiple domains—particularly in
the areas of attention, processing speed, and memory—in
most bipolar patients. These difficulties are observable at or
soon after illness onset, and persist throughout the course of
illness. Given that clinically unaffected relatives of patients
with bipolar disorder have similar but milder neurocogni-
tive impairments, such deficits may reflect genetic liability
for the illness.
Importantly, these cognitive deficits appear to have
implications for real world functioning. Although investi-
gation of the neural correlates of functional disability in
bipolar disorder is only in its nascent stages, given strong
commonalities with schizophrenia, it is anticipated that
similar relationships between structural and functional
neuroanatomic abnormalities and outcome in bipolar patients
will be identified. The rich literature in schizophrenia—and in
individuals at risk of the illness—could serve to inform areas
of future research needed in bipolar disorder.
As recommended by Harvey and colleagues [9],
approaches used in schizophrenia research—in particular,
longitudinal assessment of cognition, neurophysiology, and
psychosocial function across variations in clinical state, and
separate assessment of functional capacity and real world
functioning—will be highly informative when applied to
the study of patients with bipolar illness. A clear need exists
for objective methods of assessing real world functional
abilities, as subjective self-assessments are likely to be
influenced by current symptoms or other illness features
[9]. Thus far, few studies have investigated specific aspects
of functional status in bipolar patients and their associations
with neuroanatomic, clinical, and treatment-related factors.
Such investigations are critical for understanding the array
of determinants of disability in bipolar illness.
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